Rapid growth from $1.64 billion in 2017 to $6.07 billion in 2024 is expected in the global orphan and rare dermatology premium products market, according to business intelligence provider, GBI Research.
growth
In its latest report — Global Orphan and Rare Dermatology Drugs Market to 2024 — GBI Research has identified the changing trends in the orphan and rare dermatology market with a particular focus on systemic sclerosis (scleroderma), alopecia, epidermolysis bullosa, pemphigus Vulgaris, vitiligo and cutaneous lupus erythematosus.